Rates of infection and bleeding are not increased in patients (Pts) with MDS treated with azacitidine (AZA) compared with best supportive care (BSC)

被引：0
|
作者：
Santini, V. [1 ]
Silverman, L. [2 ]
Seymour, J. [3 ]
Fenaux, P. [4 ]
Mufti, G. [5 ]
Hellstrom-Lindberg, E. [6 ]
Sanz, G.
Finelli, C.
Backstom, J.
McKenzie, D.
Beach, C.
机构：
[1] Aou Careggi Univ Florence, UF Ematol, Florence, Italy
[2] Mt Sinai Sch Med, New York, NY USA
[3] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[4] Univ Paris 13, Hop Avicenne, F-93430 Villetaneuse, France
[5] Kings Coll London, London, England
[6] Karolinska Univ Hosp, Stockholm, Sweden
来源：
LEUKEMIA RESEARCH | 2009年 / 33卷
关键词：
D O I：
10.1016/S0145-2126(09)70208-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：S133 / S133
页数：1
相关论文
共 50 条
  • [21] Azacitidine (AZA) treatment prolongs overall survival (OS) in higher-risk MDS patients compared with conventional care regimens (CCR): Results of the AZA-001 phase III study
    Fenaux, Pierre
    Mufti, G. J.
    Santini, V.
    Finelli, C.
    Giagounidis, A.
    Schoch, R.
    List, A. F.
    Gore, S. D.
    Seymour, J. F.
    Hellstrom-Lindberg, E.
    Bennett, J. M.
    Byrd, J. C.
    Backstrom, J. T.
    Zimmerman, L. S.
    McKenzie, D. R.
    Beach, C. L.
    Silverman, L. R.
    BLOOD, 2007, 110 (11) : 250A - 251A
  • [22] A randomized phase III trial comparing sorafenib plus best supportive care (BSC) versus BSC alone in Child-Pugh B patients (pts) with advanced hepatocellular carcinoma (HCC): The BOOST study
    Daniele, Bruno
    Di Maio, Massimo
    Gallo, Ciro
    Gasbarrini, Antonio
    Carteni, Giacomo
    Di Costanzo, Giovan Giuseppe
    Craxi, Antonio
    Cabibbo, Giuseppe
    Bolondi, Luigi
    Granito, Alessandro
    Missale, Gabriele
    Frassoldati, Antonio
    Angelico, Mario
    Roselli, Mario
    Daniele, Gennaro
    Perrone, Francesco
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [23] Health-related quality of life (HRQoL) impact of pembrolizumab (pembro) versus best supportive care (BSC) in previously systemically treated patients (pts) with advanced hepatocellular carcinoma (HCC): KEYNOTE-240
    Merle, P.
    Kulkarni, A. S.
    Ryoo, B-Y.
    Cheng, A-L.
    Kudo, M.
    Bouattour, M.
    Lim, H. Y.
    Breder, V.
    Edeline, J.
    Chao, Y.
    Ogasawara, S.
    Yau, T.
    Garrido, M.
    Chan, S.
    Daniele, B.
    Norquist, J.
    Chen, E.
    Siegel, A. B.
    Zhu, A. X.
    Finn, R. S.
    ANNALS OF ONCOLOGY, 2019, 30 : 256 - 256
  • [24] Vinorelbine (VNR) plus best supportive care (BSC) vs BSC in the treatment of advanced non-small cell lung cancer (NSCLC) elderly patients (Pts). Results of a phase III randomized trial
    Gridelli, C
    Ianniello, GP
    Maiorino, L
    Brancaccio, L
    Cigolari, S
    Bilancia, D
    Aiello, R
    Zuccarino, L
    Pedicini, T
    Zonato, S
    Pappagallo, GL
    Monfardini, S
    Rossi, A
    Gallo, C
    Perrone, F
    BRITISH JOURNAL OF CANCER, 1998, 78 : 3 - 3
  • [25] Vinorelbine(VNR) plus best supportive care (BSC) vs BSC in the treatment of advanced non-small cell lung cancer (NSCLC) elderly patients (pts). Results of a phase III randomized trial
    Gridelli, C
    Ianniello, GP
    Maiorino, L
    Piantedosi, V
    Cigolari, S
    Manzione, L
    Failla, G
    Zuccarino, L
    Pedicini, T
    Vinante, O
    Castiglione, F
    Clerici, M
    Bearz, A
    Darwish, S
    Rossi, A
    Monfardini, S
    Gallo, C
    Perrone, F
    Frontini, L
    ANNALS OF ONCOLOGY, 1998, 9 : 85 - 85
  • [26] A randomized trial comparing best supportive care (BSC) versus multimodality approach (MA) to tight against cachexia in patients with cancer treated with chemotherapy.
    Forget, Frederic
    Frusch, Nicolas
    Trokay, Lisbeth
    Archen, Clementine
    Courtois, Anne-Caroline
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [27] Nintedanib plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies: Results of the phase III LUME-colon 1 study
    Van Cutsem, E.
    Yoshino, T.
    Lenz, H-J.
    Lonardi, S.
    Falcone, A.
    Limon, M. L.
    Saunders, M. P.
    Sobrero, A.
    Maiello, E.
    Park, Y. S.
    Ferreiro Monteagudo, R.
    Hong, Y. S.
    Tomasek, J.
    Taniguchi, H.
    Ciardiello, F.
    Hocke, J.
    Oum'hamed, Z.
    Vlassak, S.
    Studeny, M.
    Tabernero, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [28] A phase III trial to compare atezolizumab (atezo) vs best supportive care (BSC) following adjuvant chemotherapy in patients (pts) with completely resected NSCLC: IMpower010.
    Wakelee, Heather A.
    Altorki, Nasser K.
    Vallieres, Eric
    Zhou, Caicun
    Zuo, Yunxia
    Howland, Michael
    Xia, Fan
    Sandler, Alan
    Felip, Enriqueta
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [29] Natural history of metastatic biliary tract cancer (BTC) patients with good performance status (PS) who were treated with only best supportive care (BSC)
    Ji, Jun Ho
    Song, Haa-Na
    Kim, Rock Bum
    Oh, Sung Yong
    Lim, Ho Yeong
    Park, Joon Oh
    Park, Se Hoon
    Kim, Moon Jin
    Lee, Soon Il
    Ryou, Sung Hyeok
    Hwang, In Gyu
    Jang, Joung-Soon
    Kim, Hong Jun
    Choi, Jun Young
    Kang, Jung-Hun
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2015, 45 (03) : 256 - 260
  • [30] Treatment of high-risk MDS patients (pts) with-7/del(7q) with azacitidine (AZA) versus conventional care regimens (CCR): Effects on overall survival (OS)
    Mufti, G. J.
    Fenaux, P.
    Hellstrom-Lindberg, E.
    Santini, V.
    List, A. F.
    Gore, S.
    Seymour, J. F.
    Silverman, L. R.
    Backstrom, J.
    Beach, C. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345